

WHAT IS CLAIMED IS:

1. A composition of matter selected from the group
5 consisting of:

- a) a substantially pure or recombinant A05F12 protein
or peptide exhibiting at least about 85% sequence
identity over a length of at least about 12 amino
acids to SEQ ID NO: 2 or 4;
- 10 b) a natural sequence A05F12 comprising SEQ ID NO: 2
or 4;
- c) a fusion protein comprising A05F12 sequence;
- d) a substantially pure or recombinant A07C03 protein
or peptide exhibiting at least about 85% sequence
identity over a length of at least about 12 amino
acids to SEQ ID NO: 6, 8, or 10;
- e) a natural sequence A07C03 comprising SEQ ID NO: 6,
8, or 10;
- f) a fusion protein comprising A07C03 sequence;
- 20 g) a substantially pure or recombinant E02B02 protein
or peptide exhibiting at least about 85% sequence
identity over a length of at least about 12 amino
acids to SEQ ID NO: 12;
- h) a natural sequence E02B02 comprising SEQ ID NO:
25 12; and
- i) a fusion protein comprising E02B02 sequence.

2. A substantially pure or isolated protein
comprising a segment exhibiting sequence identity to a
30 corresponding portion of an:

- a) A05F12 of Claim 1, wherein:
- i) said homology is at least about 90% identity
and said portion is at least about 9 amino
acids;
- 35 ii) said homology is at least about 80% identity
and said portion is at least about 17 amino
acids; or

iii) said homology is at least about 70% identity and said portion is at least about 25 amino acids;

b) A07C03 of Claim 1, wherein:

i) said homology is at least about 90% identity and said portion is at least about 9 amino acids;

ii) said homology is at least about 80% identity and said portion is at least about 17 amino acids; or

iii) said homology is at least about 70% identity and said portion is at least about 25 amino acids; or

c) E02B02 of Claim 1, wherein:

i) said homology is at least about 90% identity and said portion is at least about 9 amino acids;

ii) said homology is at least about 80% identity and said portion is at least about 17 amino acids; or

iii) said homology is at least about 70% identity and said portion is at least about 25 amino acids.

3. The composition of matter of Claim 1, wherein said:

a) A05F12 comprises a mature sequence of Table 1;

b) A05F12 protein or peptide:

i) is from a warm blooded animal selected from a primate or rodent, such as a human or mouse;

ii) comprises at least one polypeptide segment of SEQ ID NO: 2 or 4;

iii) exhibits a plurality of portions exhibiting said identity;

iv) is a natural allelic variant of a primate or rodent A05F12;

v) has a length at least about 30 amino acids;

- vi) exhibits at least two non-overlapping epitopes which are specific for a primate or rodent A05F12;
- vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate or rodent A05F12;
- viii) has a molecular weight of at least 100 kD with natural glycosylation;
- ix) is a synthetic polypeptide;
- x) is attached to a solid substrate;
- xi) is conjugated to another chemical moiety;
- xii) is a 5-fold or less substitution from natural sequence; or
- xiii) is a deletion or insertion variant from a natural sequence;
- c) A07C03 comprises a mature sequence of Table 2;
- d) A07C03 protein or peptide:
- i) is from a warm blooded animal selected from a primate or rodent, such as a human or mouse;
- ii) comprises at least one polypeptide segment of SEQ ID NO: 8 or 10;
- iii) exhibits a plurality of portions exhibiting said identity;
- iv) is a natural allelic variant of a primate or rodent A07C03;
- v) has a length at least about 30 amino acids;
- vi) exhibits at least two non-overlapping epitopes which are specific for a primate or rodent A07C03;
- vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate or rodent A07C03;
- viii) has a molecular weight of at least 100 kD with natural glycosylation;
- ix) is a synthetic polypeptide;
- x) is attached to a solid substrate;
- xi) is conjugated to another chemical moiety;

- xii) is a 5-fold or less substitution from natural sequence; or
- xiii) is a deletion or insertion variant from a natural sequence;

e) E02B02 comprises a mature sequence of Table 3; or

f) E02B02 protein or peptide:

- i) is from a warm blooded animal selected from a primate, such as a human;
- ii) comprises at least one polypeptide segment of SEQ ID NO: 12;
- iii) exhibits a plurality of portions exhibiting said identity;
- iv) is a natural allelic variant of a primate E02B02;
- v) has a length at least about 30 amino acids;
- vi) exhibits at least two non-overlapping epitopes which are specific for a primate E02B02;
- vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate oE02B02;
- viii) has a molecular weight of at least 100 kD with natural glycosylation;
- ix) is a synthetic polypeptide;
- x) is attached to a solid substrate;
- xi) is conjugated to another chemical moiety;
- xii) is a 5-fold or less substitution from natural sequence; or
- xiii) is a deletion or insertion variant from a natural sequence.

4. A composition comprising:

- a) a sterile A05F12 protein or peptide of Claim 1;
- b) said A05F12 protein or peptide of Claim 1 and a carrier, wherein said carrier is:
 - i) an aqueous compound, including water, saline, and/or buffer; and/or

- ii) formulated for oral, rectal, nasal, topical, or parenteral administration;
- c) a sterile A07C03 protein or peptide of Claim 1;
- d) said A07C03 protein or peptide of Claim 1 and a carrier, wherein said carrier is:
 - i) an aqueous compound, including water, saline, and/or buffer; and/or
 - ii) formulated for oral, rectal, nasal, topical, or parenteral administration;
- e) a sterile E02B02 protein or peptide of Claim 1; or
- f) said E02B02 protein or peptide of Claim 1 and a carrier, wherein said carrier is:
 - i) an aqueous compound, including water, saline, and/or buffer; and/or
 - ii) formulated for oral, rectal, nasal, topical, or parenteral administration.

5.. The fusion protein of Claim 1, comprising:

- a) mature protein sequence of Table 1, 2, or 3;
- b) a detection or purification tag, including a FLAG, His6, or Ig sequence; or
- c) sequence of another receptor protein.

6. A kit comprising a protein or polypeptide of Claim 1, and:

- a) a compartment comprising said protein or polypeptide; and/or
- b) instructions for use or disposal of reagents in said kit.

7. A binding compound comprising an antigen binding site from an antibody, which specifically binds to a natural:

A) A05F12 protein of Claim 1, wherein:

- a) said protein is a primate or rodent protein;
- b) said binding compound is an Fv, Fab, or Fab2 fragment;

- c) said binding compound is conjugated to another chemical moiety; or
- d) said antibody:
- i) is raised against a peptide sequence of a mature polypeptide of Table 1;
 - ii) is raised against a mature primate or rodent A05F12;
 - iii) is raised to a purified human A05F12;
 - iv) is raised to a purified mouse A05F12;
 - v) is immunoselected;
 - vi) is a polyclonal antibody;
 - vii) binds to a denatured A05F12;
 - viii) exhibits a Kd to antigen of at least 30 μ M;
 - ix) is attached to a solid substrate, including a bead or plastic membrane;
 - x) is in a sterile composition; or
 - xi) is detectably labeled, including a radioactive or fluorescent label;

B) A07C03 protein of Claim 1, wherein:

- a) said protein is a primate or rodent protein;
- b) said binding compound is an Fv, Fab, or Fab2 fragment;
- c) said binding compound is conjugated to another chemical moiety; or
- d) said antibody:
 - i) is raised against a peptide sequence of a mature polypeptide of Table 2;
 - ii) is raised against a mature primate or rodent A07C03;
 - iii) is raised to a purified human A07C03;
 - iv) is raised to a purified mouse A07C03;
 - v) is immunoselected;
 - vi) is a polyclonal antibody;
 - vii) binds to a denatured A07C03;
 - viii) exhibits a Kd to antigen of at least 30 μ M;

- ix) is attached to a solid substrate,
including a bead or plastic membrane;
- x) is in a sterile composition; or
- xi) is detectably labeled, including a
radioactive or fluorescent label; or

5 C) E02B02 protein of Claim 1, wherein:

- a) said protein is a primate protein;
- b) said binding compound is an Fv, Fab, or Fab2
fragment;
- 10 c) said binding compound is conjugated to
another chemical moiety; or
- d) said antibody:
 - i) is raised against a peptide sequence of
a mature polypeptide of Table 3;
 - ii) is raised against a mature primate
E02B02;
 - iii) is raised to a purified human E02B02;
 - iv) is immunoselected;
 - v) is a polyclonal antibody;
 - vi) binds to a denatured E02B02;
 - vii) exhibits a Kd to antigen of at least
30 μ M;
 - viii) is attached to a solid substrate,
including a bead or plastic membrane;
 - ix) is in a sterile composition; or
 - x) is detectably labeled, including a
radioactive or fluorescent label

8. A kit comprising said binding compound of Claim
7, and:

- a) a compartment comprising said binding compound;
and/or
- b) instructions for use or disposal of reagents in
said kit.

9. The kit of Claim 8 capable of making a
qualitative or quantitative analysis.

10. A composition comprising:

- a) a sterile binding compound of Claim 7; or
- b) said binding compound of Claim 7 and a carrier,
wherein said carrier is:
 - i) an aqueous compound, including water, saline,
and/or buffer; and/or
 - ii) formulated for oral, rectal, nasal, topical,
or parenteral administration.

11. An isolated or recombinant nucleic acid encoding
a protein or peptide or fusion protein of Claim 1, wherein:

- a) said A05F12 protein or peptide is from a mammal,
including a primate or rodent;
- b) said nucleic acid:
 - i) encodes an antigenic peptide sequence of
Table 1;
 - ii) encodes a plurality of antigenic peptide
sequences of Table 1;
 - iii) exhibits at least about 80% identity to a
natural cDNA encoding said segment;
 - iv) is an expression vector;
 - v) further comprises an origin of replication;
 - vi) is from a natural source;
 - vii) comprises a detectable label;
 - viii) comprises synthetic nucleotide sequence;
 - ix) is less than 6 kb, preferably less than 3
kb;
 - x) is from a mammal, including a primate or
rodent;
 - xi) comprises a natural full length coding
sequence;
 - xii) is a hybridization probe for a gene
encoding said A05F12; or
 - xiii) is a PCR primer, PCR product, or
mutagenesis primer;

- c) said A05C03 is from a mammal, including a primate or rodent;
- d) said nucleic acid:
- i) encodes an antigenic peptide sequence of Table 2;
 - ii) encodes a plurality of antigenic peptide sequences of Table 2;
 - iii) exhibits at least about 80% identity to a natural cDNA encoding said segment;
 - iv) is an expression vector;
 - v) further comprises an origin of replication;
 - vi) is from a natural source;
 - vii) comprises a detectable label;
 - viii) comprises synthetic nucleotide sequence;
 - ix) is less than 6 kb, preferably less than 3 kb;
 - x) is from a mammal, including a primate or rodent;
 - xi) comprises a natural full length coding sequence;
 - xii) is a hybridization probe for a gene encoding said A07C03; or
 - xiii) is a PCR primer, PCR product, or mutagenesis primer;
- e) said E02B02 is from a mammal, including a primate; or
- f) said nucleic acid:
- i) encodes an antigenic peptide sequence of Table 3;
 - ii) encodes a plurality of antigenic peptide sequences of Table 3;
 - iii) exhibits at least about 80% identity to a natural cDNA encoding said segment;
 - iv) is an expression vector;
 - v) further comprises an origin of replication;
 - vi) is from a natural source;
 - vii) comprises a detectable label;

15. The kit of Claim 14 capable of making a qualitative or quantitative analysis.

16. A nucleic acid which:

- a) hybridizes under wash conditions of 30° C and less than 2M salt to SEQ ID NO: 1 or 3;
- b) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate or rodent A05F12;
- c) hybridizes under wash conditions of 30° C and less than 2M salt to SEQ ID NO: 5, 7, or 9;
- d) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate or rodent A07C03;
- e) hybridizes under wash conditions of 30° C and less than 2M salt to SEQ ID NO: 11; or
- b) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate E02B02.

17. The nucleic acid of Claim 16, wherein:

- a) said wash conditions are at 45° C and/or 500 mM salt; or
- b) said identity is at least 90% and/or said stretch is at least 55 nucleotides.

18. The nucleic acid of Claim 17, wherein:

- a) said wash conditions are at 55° C and/or 150 mM salt; or
- b) said identity is at least 95% and/or said stretch is at least 75 nucleotides.

19. A method of modulating physiology or development of a cell or tissue culture cells comprising contacting said cell with:

- a) a binding composition of Claim 7, which binds to a primate or rodent A05F12;

- b) a binding composition of Claim 7, which binds to a primate or rodent A07C03;
- c) a binding composition of Claim 7, which binds to a primate E01B02;
- d) a antisense nucleic acid which blocks expression of a primate or rodent A05F12;
- e) a antisense nucleic acid which blocks expression of a primate or rodent A07C03; or
- f) a antisense nucleic acid which blocks expression of a primate E02B02.

5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995